The Oncosil product is not competing with chemotherapy protocols - it is looking to be an adjuvant treatment with those protocols. No chemotherapy protocols have been shown to particularly effective in pancreatic cancer, and this is very unlikely to change in the short to medium term: targeted antibody based or immunotherapy have been where the big gains have been made in medical oncology in recent years, but none of these work in pancreatic cancer. Most pancreatic cancer is inoperable at diagnosis and chemo/radiotherapy combinations make sense in such situations to try and buy some months - the latter, however, is too toxic for most if delivered in the standard manner. Minimally invasive administration of radiation is an attractive concept, and is likely to attract customers even if there is no solid data backing its use as it is relatively safe, and actually quite cheap when compared to courses of chemotherapy. The achievement of a CE mark is significant in that this opens up markets all around the world for use by private paying customers. Phase 3 trials would be required for it to be a funded option in most jurisdictions, but a CE mark allows registration in most countries.
OSL Price at posting:
11.5¢ Sentiment: Buy Disclosure: Held
(20min delay)